Key result
GLP-2 increases postprandial lipids and apoB48 expression via an nNOS-dependent mechanism.
Why the study?
Intestinal hormone GLP-2 regulates dietary fat uptake and increases chylomicron production in insulin-resistant states, but the mechanisms by which GLP-2 enhances chylomicron production and the specific role of neuronal nitric oxide synthase-mediated nitric oxide generation remained unclear.
Does neuronal nitric oxide synthase (nNOS) signaling mediate the effects of GLP-2 on postprandial dietary fat absorption and chylomicron production in mice?
Does neuronal nitric oxide synthase (nNOS) signaling mediate the effects of GLP-2 on postprandial dietary fat absorption and chylomicron production in mice?
Demonstrates that neuronal nitric oxide synthase (nNOS)-generated NO is required for GLP-2-mediated postprandial lipid absorption and chylomicron production, identifying a potential therapeutic target for diabetic dyslipidemia.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for GLP-2 in T2D dyslipidemia; human trials required before any clinical consideration.
Objective: Postprandial dyslipidemia, a condition commonly presented in individuals with type 2 diabetes (T2D), is characterized by the overproduction of triglyceride (TG)-rich lipoproteins (TRL). This results in excess atherogenic chylomicron (CM) remnants in circulation, significantly increasing the risk of cardiovascular disease (CVD). Using a Syrian golden hamster model, our laboratory has revealed that intestinal hormone glucagon-like peptide-2 (GLP-2) regulates dietary fat uptake and increases CM production in insulin-resistant states. However, the mechanisms by which GLP-2 enhances CM production remain unclear. Previous studies have implicated nitric oxide (NO) in the actions of GLP-2, demonstrating the requirement of NO in CM secretion. Therefore, this study investigated the role of neuronal NO synthase (nNOS)-mediated NO generation in lipid uptake and CM formation. Methods: nNOS-/- and C57BL/6 (WT) mice received an intraduodenal injection of olive oil, followed by an acute intraperitoneal (i.p.) injection of GLP-2 (0.25mg/kg; n=7) or vehicle (PBS; n=8). Blood samples were collected over a 2-hour period to assess postprandial lipid accumulation, and TRL fractions were isolated via ultracentrifugation. Immunoblotting was used to measure plasma apolipoprotein B48 (apoB48) protein expression. Results: While GLP-2-treated WT mice showed characteristic rises in postprandial TG and cholesterol in whole plasma and TRL fractions, the effect of GLP-2 in nNOS-/- mice was abolished. The effect of GLP-2 on postprandial plasma apoB48 protein expression was also abolished in nNOS-/- mice relative to GLP-2-treated WT mice. Conclusions: These findings demonstrate a novel mechanism in which nNOS-generated NO is crucial for GLP-2-mediated lipid absorption and CM production in the postprandial state. Understanding this pathway will provide insight for future therapeutic interventions to treat lipid disorders in T2D.
No takes yet. Share an insight, caveat, or question.
Grande et al. (2020) studied Postprandial dyslipidemia / lipid absorption model (n=15). Glucagon-like peptide-2 (GLP-2) vs. Vehicle (PBS) intraperitoneal injection was evaluated on Postprandial triglyceride (TG) and cholesterol in whole plasma and TRL fractions, and plasma apoB48 protein expression. GLP-2 increased postprandial triglycerides, cholesterol, and apoB48 expression in wild-type mice over 2 hours, an effect abolished in nNOS-/- mice.
Synapse has enriched 10 related papers. Consider them for comparative context: